{'52WeekChange': 0.43356645,
 'SandP52WeekChange': 0.0644362,
 'address1': '4796 Executive Drive',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 4.1,
 'askSize': 1800,
 'averageDailyVolume10Day': 308762,
 'averageVolume': 277739,
 'averageVolume10days': 308762,
 'beta': 2.355182,
 'beta3Year': None,
 'bid': 4.1,
 'bidSize': 1400,
 'bookValue': 0.972,
 'category': None,
 'circulatingSupply': None,
 'city': 'San Diego',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 4.18,
 'dayLow': 3.91,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -2.58,
 'enterpriseToRevenue': 195.825,
 'enterpriseValue': 111228640,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '619-291-9190',
 'fiftyDayAverage': 3.6032858,
 'fiftyTwoWeekHigh': 4.39,
 'fiftyTwoWeekLow': 1.53,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 29189053,
 'forwardEps': -1.09,
 'forwardPE': -3.7614677,
 'fromCurrency': None,
 'fullTimeEmployees': 49,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.0035299999,
 'heldPercentInstitutions': 0.63449,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/otonomy.com',
 'longBusinessSummary': 'Otonomy, Inc., a biopharmaceutical company, develops '
                        'therapeutics for neurotology in the United States. '
                        'The company offers OTIPRIO, a ciprofloxacin otic '
                        'suspension for use during tympanostomy tube placement '
                        'surgery in pediatric patients. It also develops '
                        'OTIVIDEX, a sustained-exposure formulation of the '
                        'steroid dexamethasone in Phase III clinical trial for '
                        "the treatment of Ménière's disease; OTO-313, a "
                        'sustained-exposure formulation of '
                        'N-methyl-D-aspartate receptor antagonist gacyclidine, '
                        'which is in Phase I/II clinical trial to treat '
                        'tinnitus; and OTO-413, a proprietary formulation of '
                        'brain-derived neurotrophic factor that is in Phase '
                        'I/II clinical trial for the repair of cochlear '
                        'synaptopathy and the treatment of speech-in-noise '
                        'hearing difficulties. In addition, the company '
                        'develops OTO-510, a sustained-exposure formulation of '
                        'small molecule otoprotectant for the prevention of '
                        'cisplatin-induced hearing loss; and OTO-6XX induces '
                        'hair cell regeneration for the treatment of severe '
                        'hearing loss. The company has license agreements with '
                        'University of California and DURECT Corporation; and '
                        'strategic collaboration with Applied Genetic '
                        'Technologies Corporation to develop and commercialize '
                        'gene therapy for congenital hearing loss. Otonomy, '
                        'Inc. was founded in 2008 and is headquartered in San '
                        'Diego, California.',
 'longName': 'Otonomy, Inc.',
 'market': 'us_market',
 'marketCap': 197386288,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_60978778',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -44454000,
 'nextFiscalYearEnd': 1640908800,
 'open': 3.95,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.14,
 'phone': '619-323-2200',
 'previousClose': 4.02,
 'priceHint': 4,
 'priceToBook': 4.2181067,
 'priceToSalesTrailing12Months': 347.51108,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 4.18,
 'regularMarketDayLow': 3.91,
 'regularMarketOpen': 3.95,
 'regularMarketPreviousClose': 4.02,
 'regularMarketPrice': 3.95,
 'regularMarketVolume': 183432,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 48143000,
 'sharesPercentSharesOut': 0.0058,
 'sharesShort': 178519,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 141270,
 'shortName': 'Otonomy, Inc.',
 'shortPercentOfFloat': 0.0063,
 'shortRatio': 0.96,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'OTIC',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.445,
 'twoHundredDayAverage': 2.9423382,
 'volume': 183432,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.otonomy.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '92121'}